Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Shire Gets Peptide Specialist Jerini
July 14, 2008
| A version of this story appeared in
Volume 86, Issue 28
Shire has agreed to acquire Berlin-based Jerini, a drug discovery and development firm specializing in peptides, for $555 million. Shire's primary interest in Jerini is its lead compound, Firazyr, a treatment for hereditary angioedema. Jerini is awaiting final European Union approval of the compound and is anticipating a launch this year. Firazyr was rejected by FDA because of efficacy concerns, but a Jerini spokeswoman says the firm has submitted a response and is hopeful of U.S. approval.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter